Vestal Point Capital LP Acquires Shares of 83,333 Tenax Therapeutics, Inc. (NASDAQ:TENX)

Vestal Point Capital LP acquired a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 83,333 shares of the specialty pharmaceutical company’s stock, valued at approximately $288,000. Vestal Point Capital LP owned about 2.44% of Tenax Therapeutics at the end of the most recent quarter.

Separately, Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics during the 3rd quarter worth about $173,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Guggenheim assumed coverage on Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 target price on the stock. William Blair began coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating for the company. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. StockNews.com began coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating for the company. Finally, Leerink Partners initiated coverage on Tenax Therapeutics in a report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Tenax Therapeutics Trading Up 3.1 %

Shares of NASDAQ:TENX opened at $5.33 on Friday. Tenax Therapeutics, Inc. has a 1-year low of $2.77 and a 1-year high of $31.20. The firm has a fifty day moving average price of $4.19 and a 200 day moving average price of $3.77.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.